Search

everythinglearnresearchcommunity

for

Search:↓

Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Licorice component glycyrrhizic acid may reduce skin side effects from cancer treatment.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

AHCC reduces hair loss and liver injury caused by chemotherapy in rodents.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

CS12192 effectively treats alopecia areata with better safety than current options.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

Upadacitinib effectively treats severe alopecia areata and is safe.

The drug combination was safe and showed promise in treating advanced tumors.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.

Methotrexate and azathioprine are equally effective and well-tolerated for treating lichen planopilaris.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.